Pharmacyclics Llc Drug Patent Portfolio
Pharmacyclics Llc owns 1 orange book drug protected by 82 US patents Given below is the list of Pharmacyclics Llc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12201690 | Formulations/compositions comprising ibrutinib | 14 Jun, 2039 | Active |
| US10010507 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | 03 Sep, 2036 | Active |
| US10213386 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Sep, 2036 | Active |
| US10828259 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Sep, 2036 | Active |
| US9655857 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Sep, 2036 | Active |
| US10010507 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor | 03 Mar, 2036 | Active |
| US10213386 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Mar, 2036 | Active |
| US10828259 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Mar, 2036 | Active |
| US9655857 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor | 03 Mar, 2036 | Active |
| US10463668 | Methods of treating and preventing graft versus host disease | 24 Apr, 2035 | Active |
| US10695350 | Methods of treating and preventing graft versus host disease | 24 Apr, 2035 | Active |
| US9795604 | Methods of treating and preventing graft versus host disease | 24 Apr, 2035 | Active |
| US10463668 | Methods of treating and preventing graft versus host disease | 24 Oct, 2034 | Active |
| US10695350 | Methods of treating and preventing graft versus host disease | 24 Oct, 2034 | Active |
| US9795604 | Methods of treating and preventing graft versus host disease | 24 Oct, 2034 | Active |
| US9296753 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 30 Apr, 2034 | Active |
| US9540382 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 18 Feb, 2034 | Active |
| US10106548 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US10125140 | Crystalline forms of a bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US10294231 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US10294232 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US10752634 | Crystalline forms of a brutons tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US10961251 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US9713617 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US9725455 | Crystalline forms of a bruton's tyrosine kinase inhibitor | 03 Dec, 2033 | Active |
| US9296753 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 30 Oct, 2033 | Active |
| US9540382 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 18 Aug, 2033 | Active |
| US10106548 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10125140 | Crystalline forms of a bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10294231 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10294232 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10752634 | Crystalline forms of a brutons tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10961251 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US9713617 | Crystalline forms of a Bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US9725455 | Crystalline forms of a bruton's tyrosine kinase inhibitor | 03 Jun, 2033 | Active |
| US10004746 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US10016435 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US10478439 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US10653696 | Use of inhibitors of bruton's tyrosine kinase (BTK) | 03 Dec, 2031 | Active |
| US10751342 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US8754090 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US8999999 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US9125889 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US9801881 | Use of inhibitors of bruton's tyrosine kinase (BTK) | 03 Dec, 2031 | Active |
| US9801883 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Dec, 2031 | Active |
| US9814721 | Use of inhibitors of bruton'S tyrosine kinase (BTK) | 03 Dec, 2031 | Active |
| US10004746 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US10016435 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US10478439 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US10653696 | Use of inhibitors of bruton's tyrosine kinase (BTK) | 03 Jun, 2031 | Active |
| US10751342 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US11672803 | Use of inhibitors of Brutons tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US8754090 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US8999999 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US9125889 | Use of inhibitors of Bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US9801881 | Use of inhibitors of bruton's tyrosine kinase (BTK) | 03 Jun, 2031 | Active |
| US9801883 | Use of inhibitors of bruton's tyrosine kinase (Btk) | 03 Jun, 2031 | Active |
| US9814721 | Use of inhibitors of bruton'S tyrosine kinase (BTK) | 03 Jun, 2031 | Active |
| US8008309 | Inhibitors of bruton's tyrosine kinase | 13 May, 2028 | Active |
| US8008309 | Inhibitors of bruton's tyrosine kinase | 13 Nov, 2027 | Active |
| US8563563 | Inhibitors of bruton's tyrosine kinase | 26 Oct, 2027 | Active |
| US7514444 | Inhibitors of bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8476284 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8497277 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8697711 | Inhibitors of bruton'S tyrosine kinase | 28 Jun, 2027 | Active |
| US8703780 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8735403 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8754091 | Inhibitors of bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8952015 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8957079 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US9181257 | Inhibitors of Bruton's tyrosine kinase | 28 Jun, 2027 | Active |
| US8563563 | Inhibitors of bruton's tyrosine kinase | 26 Apr, 2027 | Active |
| US7514444 | Inhibitors of bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8476284 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8497277 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8697711 | Inhibitors of bruton'S tyrosine kinase | 28 Dec, 2026 | Active |
| US8703780 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8735403 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8754091 | Inhibitors of bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8952015 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US8957079 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
| US9181257 | Inhibitors of Bruton's tyrosine kinase | 28 Dec, 2026 | Active |
Latest Legal Activities on Pharmacyclics Llc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Pharmacyclics Llc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 13 Jun, 2024 | US9540382 |
|
Request for Trial Granted
Critical
| 01 May, 2024 | US11672803 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Apr, 2024 | US10828259 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2024 | US10751342 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 11 Jan, 2024 | US10752634 |
| Letter from FDA or Dept of Agriculture re PTE application | 18 Dec, 2023 | US8008309 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 10 Nov, 2023 | US10695350 |
| Petition Requesting Trial | 06 Nov, 2023 | US11672803 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 12 Oct, 2023 | US10653696 (Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Aug, 2023 | US9296753 |
|
Email Notification
Critical
| 13 Jun, 2023 | US11672803 (Litigated) |
|
Patent Issue Date Used in PTA Calculation
Critical
| 13 Jun, 2023 | US11672803 (Litigated) |
|
Recordation of Patent Grant Mailed
Critical
| 13 Jun, 2023 | US11672803 (Litigated) |
|
Electronic Review
Critical
| 13 Jun, 2023 | US11672803 (Litigated) |
| Patent eGrant Notification | 13 Jun, 2023 | US11672803 (Litigated) |
Pharmacyclics Llc's Drug Patent Litigations
Pharmacyclics Llc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 20, 2015, against patent number US8754090. The petitioner Coalition for Affordable Drugs IV LLC, challenged the validity of this patent, with Pharmacyclics, Inc. as the respondent. Click below to track the latest information on how companies are challenging Pharmacyclics Llc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US11672803 | November, 2023 |
Trial Instituted
(01 May, 2024)
| Pharmacyclics LLC | BeiGene USA, Inc. et al. |
| US9795604 | March, 2019 |
Final Written Decision
(24 Sep, 2020)
| Pharmacyclics LLC et al. | Sandoz Inc. et al. |
| US8754090 | April, 2015 |
Terminated-Denied
(19 Oct, 2015)
| Pharmacyclics, Inc. | Coalition for Affordable Drugs IV LLC |
Pharmacyclics Llc Drug Patents' Oppositions Filed in EPO
Pharmacyclics Llc drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Oct 17, 2018, by Generics (U.K.) Limited. This opposition was filed on patent number EP12166302A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12166302A | Oct, 2018 | Generics (U.K.) Limited | Revoked |
Pharmacyclics Llc's Family Patents
Pharmacyclics Llc drugs have patent protection in a total of 43 countries. It's US patent count contributes only to 35.1% of its total global patent coverage. 3 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Pharmacyclics Llc Drug List
Given below is the complete list of Pharmacyclics Llc's drugs and the patents protecting them.
1. Imbruvica
Imbruvica is protected by 82 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US12201690 | Formulations/compositions comprising ibrutinib |
14 Jun, 2039
(14 years from now)
| Active |
| US10010507
(Pediatric)
| Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
03 Sep, 2036
(11 years from now)
| Active |
| US10213386
(Pediatric)
| Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Sep, 2036
(11 years from now)
| Active |
| US10828259
(Pediatric)
| Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Sep, 2036
(11 years from now)
| Active |
| US9655857
(Pediatric)
| Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Sep, 2036
(11 years from now)
| Active |
| US10010507 | Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor |
03 Mar, 2036
(10 years from now)
| Active |
| US10213386 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Mar, 2036
(10 years from now)
| Active |
| US10828259 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Mar, 2036
(10 years from now)
| Active |
| US9655857 | Pharmaceutical formulations of a Bruton's tyrosine kinase inhibitor |
03 Mar, 2036
(10 years from now)
| Active |
| US10463668
(Pediatric)
| Methods of treating and preventing graft versus host disease |
24 Apr, 2035
(9 years from now)
| Active |
| US10695350
(Pediatric)
| Methods of treating and preventing graft versus host disease |
24 Apr, 2035
(9 years from now)
| Active |
| US9795604
(Pediatric)
| Methods of treating and preventing graft versus host disease |
24 Apr, 2035
(9 years from now)
| Active |
| US10463668 | Methods of treating and preventing graft versus host disease |
24 Oct, 2034
(9 years from now)
| Active |
| US10695350 | Methods of treating and preventing graft versus host disease |
24 Oct, 2034
(9 years from now)
| Active |
| US9795604 | Methods of treating and preventing graft versus host disease |
24 Oct, 2034
(9 years from now)
| Active |
| US9296753
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
30 Apr, 2034
(8 years from now)
| Active |
| US9540382
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
18 Feb, 2034
(8 years from now)
| Active |
| US10106548
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US10125140
(Pediatric)
| Crystalline forms of a bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US10294231
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US10294232
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US10752634
(Pediatric)
| Crystalline forms of a brutons tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US10961251
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US9713617
(Pediatric)
| Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US9725455
(Pediatric)
| Crystalline forms of a bruton's tyrosine kinase inhibitor |
03 Dec, 2033
(8 years from now)
| Active |
| US9296753 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
30 Oct, 2033
(8 years from now)
| Active |
| US9540382 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
18 Aug, 2033
(8 years from now)
| Active |
| US10106548 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10125140 | Crystalline forms of a bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10294231 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10294232 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10752634 | Crystalline forms of a brutons tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10961251 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US9713617 | Crystalline forms of a Bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US9725455 | Crystalline forms of a bruton's tyrosine kinase inhibitor |
03 Jun, 2033
(8 years from now)
| Active |
| US10004746
(Pediatric)
| Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US10016435
(Pediatric)
| Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US10478439
(Pediatric)
| Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US10653696
(Pediatric)
| Use of inhibitors of bruton's tyrosine kinase (BTK) |
03 Dec, 2031
(6 years from now)
| Active |
| US10751342
(Pediatric)
| Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US8754090
(Pediatric)
| Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US8999999
(Pediatric)
| Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US9125889
(Pediatric)
| Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US9801881
(Pediatric)
| Use of inhibitors of bruton's tyrosine kinase (BTK) |
03 Dec, 2031
(6 years from now)
| Active |
| US9801883
(Pediatric)
| Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Dec, 2031
(6 years from now)
| Active |
| US9814721
(Pediatric)
| Use of inhibitors of bruton'S tyrosine kinase (BTK) |
03 Dec, 2031
(6 years from now)
| Active |
| US10004746 | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US10016435 | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US10478439 | Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US10653696 | Use of inhibitors of bruton's tyrosine kinase (BTK) |
03 Jun, 2031
(6 years from now)
| Active |
| US10751342 | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US11672803 | Use of inhibitors of Brutons tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US8754090 | Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US8999999 | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US9125889 | Use of inhibitors of Bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US9801881 | Use of inhibitors of bruton's tyrosine kinase (BTK) |
03 Jun, 2031
(6 years from now)
| Active |
| US9801883 | Use of inhibitors of bruton's tyrosine kinase (Btk) |
03 Jun, 2031
(6 years from now)
| Active |
| US9814721 | Use of inhibitors of bruton'S tyrosine kinase (BTK) |
03 Jun, 2031
(6 years from now)
| Active |
| US8008309
(Pediatric)
| Inhibitors of bruton's tyrosine kinase |
13 May, 2028
(3 years from now)
| Active |
| US8008309 | Inhibitors of bruton's tyrosine kinase |
13 Nov, 2027
(2 years from now)
| Active |
| US8563563
(Pediatric)
| Inhibitors of bruton's tyrosine kinase |
26 Oct, 2027
(2 years from now)
| Active |
| US7514444
(Pediatric)
| Inhibitors of bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8476284
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8497277
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8697711
(Pediatric)
| Inhibitors of bruton'S tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8703780
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8735403
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8754091
(Pediatric)
| Inhibitors of bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8952015
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8957079
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US9181257
(Pediatric)
| Inhibitors of Bruton's tyrosine kinase |
28 Jun, 2027
(2 years from now)
| Active |
| US8563563 | Inhibitors of bruton's tyrosine kinase |
26 Apr, 2027
(1 year, 11 months from now)
| Active |
| US7514444 | Inhibitors of bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8476284 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8497277 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8697711 | Inhibitors of bruton'S tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8703780 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8735403 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8754091 | Inhibitors of bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8952015 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US8957079 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
| US9181257 | Inhibitors of Bruton's tyrosine kinase |
28 Dec, 2026
(1 year, 7 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Imbruvica's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List